Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from ra-beyond up to 7 years of treatment

Ítems similars

• Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study
  per: Caporali, R, et al.
  Publicat: (2024)
• Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
  per: Humby, F, et al.
  Publicat: (2019)
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
  per: Keystone, E, et al.
  Publicat: (2015)
• Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
  per: Strand, V, et al.
  Publicat: (2021)
• Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
  per: Taylor, P, et al.
  Publicat: (2019)